Bimonthly Administered Long-Acting Cabotegravir and Rilpivirine Are Highly Effective and Well-Tolerated in People With Human Immunodeficiency Virus Above 65 Years
Open Forum Infectious Diseases · 26.12.2025 · 13 (1)
DOI: 10.1093/ofid/ofaf817 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 06.01.2026. Verfasst von Andrea Calcagno und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GEPPO, ViiV Health Care, MSD.
Abstract (Originalsprache)
Older people with HIV (PWH) may benefit from long-acting cabotegravir/rilpivirine (LA-CAB/RPV), a population underrepresented in trials and observational cohorts. In the GEPPO cohort, 135 PWH >65 years of age received bimonthly LA-CAB/RPV. After 17.4 months, virological suppression (HIV-RNA <50 copies/mL) was maintained in all, while 15 participants discontinued them (11.1%, 10% in the first 12 months): 1 participant with isolated HbCAb at baseline showed a late HBV reactivation (19.4 months after starting). These findings support LA-CAB/RPV's efficacy and tolerability in older PWH.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
- Infectious Disease Unit, Università Vita Salute San Raffaele, Milano, Italy.
- Department of Infectious Diseases, University of Milan, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy.
- Unit of Biostatistics and Bioinformatics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
- Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy.
- Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy.
ORCID-Profile: Andrea Calcagno, Jovana Milic, Maria Mazzitelli, Silvia Nozza, Giovanni Guaraldi, Emanuele Focà
Förderung
- GEPPO
- ViiV Health Care
- MSD
Zitieren
APA
Calcagno, A., Candela, C., Riva, A., Calza, S., Fioretti, B., Gardini, S., Milic, J., Celesia, B. M., Orofino, G., De Vito, A., De Socio, G. V., Cossu, M. V., Barrera, F., Mazzitelli, M., Nozza, S., Guaraldi, G., Focà, E., & GEPPO Study Group (2025). Bimonthly Administered Long-Acting Cabotegravir and Rilpivirine Are Highly Effective and Well-Tolerated in People With Human Immunodeficiency Virus Above 65 Years. Open Forum Infectious Diseases, 13(1). https://doi.org/10.1093/ofid/ofaf817
Vancouver
Calcagno A, Candela C, Riva A, Calza S, Fioretti B, Gardini S, et al. Bimonthly Administered Long-Acting Cabotegravir and Rilpivirine Are Highly Effective and Well-Tolerated in People With Human Immunodeficiency Virus Above 65 Years. Open Forum Infectious Diseases. 2025;13(1). doi:10.1093/ofid/ofaf817
BibTeX
@article{Calcagno2025,
author = {Calcagno, Andrea and Candela, Caterina and Riva, Agostino and Calza, Stefano and Fioretti, Benedetta and Gardini, Samuele and Milic, Jovana and Celesia, Benedetto Maurizio and Orofino, Giancarlo and De Vito, Andrea and De Socio, Giuseppe Vittorio and Cossu, Maria Vittoria and Barrera, Federica and Mazzitelli, Maria and Nozza, Silvia and Guaraldi, Giovanni and Focà, Emanuele and GEPPO Study Group, GEPPO Study Group},
title = {Bimonthly Administered Long-Acting Cabotegravir and Rilpivirine Are Highly Effective and Well-Tolerated in People With Human Immunodeficiency Virus Above 65 Years},
journal = {Open Forum Infectious Diseases},
year = {2025},
volume = {13},
number = {1},
doi = {10.1093/ofid/ofaf817}
}
EUVIMED